A late-stage trial found that a personalized mRNA vaccine for melanoma reduced the risk of death or cancer recurrence.

What it means

A Phase 3 clinical trial found that a personalized mRNA vaccine, tailored to each patient's tumor DNA, reduced the risk of death or melanoma recurrence by 42% compared with standard therapy alone. The vaccine, developed by Merck and Moderna, uses artificial intelligence to design the custom jab within weeks. Experts described the result as a 'game-changer' for melanoma treatment.

Accuracy & sourcesGrounded

The claim is solid, based on data from a large, late-stage randomized trial presented at a medical conference and reported by multiple reputable outlets such as The Telegraph, NBC News, and STAT News. Primary source likely includes a formal trial publication or press release from the drug manufacturers (Merck/Moderna) and the European Society for Medical Oncology (ESMO) meeting.

How new

Genuinely new: the trial results were publicly released and reported in late October 2026.

Past coverage